Clinical Trials Logo
  1. Home
  2. Bladder Cancer
  3. NCT03193970
  4. Details
NCT03193970 Clinical Trial

Measuring Surgical Recovery After Radical Cystectomy

Bladder Cancer Clinical Trial

Official title:
Measuring Surgical Recovery After Radical Cystectomy

Clinical Trial Details — Status: Recruiting

Administrative data
NCT number NCT03193970
Other study ID # PA15-0026
Secondary ID NCI-2018-01433
Status Recruiting
Phase
First received
Last updated
Start date April 30, 2015
Est. completion date December 31, 2034

Study information
Verified date April 2024
Source M.D. Anderson Cancer Center
Contact Neema Navai, MD
Phone 713-792-3950
Email nnavai@mdanderson.org
Is FDA regulated No
Health authority
Study type Observational [Patient Registry]

Clinical Trial Summary

The intent of this study is to establish a registry of post-surgical outcomes in patients undergoing radical cystectomy at MD Anderson Cancer Center and the collaborating institutions. The goals of this initiative are to obtain a detailed baseline of multiple patient-reported outcomes (PRO) and clinician-reported outcomes (CRO) as well as various presenting conditions associated with them, so that future quality improvement interventions can be evaluated accurately as to their relative contribution to improved outcomes.

Recruitment information / eligibility
Status Recruiting
Enrollment 2000
Est. completion date December 31, 2034
Est. primary completion date December 31, 2034
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Bladder cancer patients undergoing radical cystectomy at the MD Anderson Cancer Center and the collaborating centers. Exclusion Criteria: N/A

Study Design

Related Conditions & MeSH terms

Intervention

Behavioral:
• Post-Operative Recovery Registry
Multi-institutional prospective database of patients with bladder cancer undergoing radical cystectomy.

Locations
Country Name City State
United States Emory University Atlanta Georgia
United States John Hopkins Medical Institutions Baltimore Maryland
United States University of Chicago Chicago Illinois
United States University of Texas - Southwestern Dallas Texas
United States Spectrum Health Medical Group Grand Rapids Michigan
United States University of Texas MD Anderson Cancer Center Houston Texas
United States University of Kansas Medical Center Lawrence Kansas
United States Winthrop University Hospital Mineola New York
United States University of Rochester Rochester New York
United States University of California - San Francisco San Francisco California
United States Stanford University Stanford California

Sponsors (1)
Lead Sponsor Collaborator
M.D. Anderson Cancer Center

Country where clinical trial is conducted

United States, 

Outcome
Type Measure Description Time frame Safety issue
Primary Post-Surgical Outcomes in Patients Undergoing Radical Cystectomy Post-surgical outcomes determined from patient-reported assessment of symptom burden using the MD Anderson Symptom Inventory (MDASI-BLC form). 3 months
See also
  Status Clinical Trial Phase
Not yet recruiting NCT06034015 - A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Doses of APL-1501 Extended Release (ER) Capsules Compared to APL-1202 Immediate Release (IR) Tablets in Healthy Volunteers Phase 1
Recruiting NCT04235764 - En-bloc Transurethral Resection of Bladder Tumor (En-bloc TURBT) Specimens Using a Redesigned Surgical Resectoscope Device
Completed NCT02371447 - VPM1002BC in Recurrent Non-muscle Invasive Bladder Cancer Phase 1/Phase 2
Recruiting NCT04081246 - Transurethral Modified En Bloc Resection For Large Bladder Tumours. N/A
Recruiting NCT06059547 - Neoadjuvant Immunotherapy in Combination With the Anti-GDF-15 Antibody Visugromab (CTL-002) for Treatment of Muscle Invasive Bladder Cancer Phase 2
Terminated NCT04779489 - Checkpoint Inhibitor and Radiation Therapy in Bulky, Node-Positive Bladder Cancer N/A
Not yet recruiting NCT04493489 - Propranolol Adjuvant Treatment of Bladder Cancer Phase 2
Completed NCT03520231 - Study Comparing Denosumab With Standard Treatment in Urothelial Cancer Patients With Bone Metastases Phase 2
Recruiting NCT04537221 - Nordic Cystectomy Study III - Transfusion
Withdrawn NCT03007771 - Magnetic Resonance-guided High-Intensity Focused Ultrasound (MR-HIFU) Used for Mild Hyperthermia Phase 1
Completed NCT01955408 - Severity of Overactive Bladder Symptoms in Patients After Synergo Treatment N/A
Completed NCT04487457 - Prospective Study to Evaluate the Blood Kinetics of Immune Cells and Immunosuppressive Cytokines After Exposure to an Immunity Checkpoint Inhibitor (ICI): Study of the Impact of Chemotherapy
Active, not recruiting NCT04383210 - Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors Phase 2
Recruiting NCT05562791 - A Study of 68Gallium PSMA-PET/CT Scans in People With Bladder Cancer Phase 1
Completed NCT00199849 - NY-ESO-1 Plasmid DNA (pPJV7611) Cancer Vaccine Phase 1
Completed NCT02781428 - To Detect the Sensitivity of the UroMark Assay
Recruiting NCT04738630 - Study of HX008 for the Treatment of BCG-Unresponsive Non-muscle Invasive Bladder Cancer Phase 2
Completed NCT03980041 - Study to Evaluate the Efficacy/Safety of IPI-549 in Combination With Nivolumab in Patients With Advanced Urothelial Carcinoma (MARIO-275) Phase 2
Active, not recruiting NCT03978624 - Window of Opportunity Study of Pembrolizumab Alone and in Combinations in Bladder Cancer Phase 2
Completed NCT04534309 - Behavioral Weight Loss Program for Cancer Survivors in Maryland N/A

External Links